Introduction {#sec1-0300060519899780}
============

Although there has been a sharp decline in the incidence of gastric cancer (GC) over the past century, it remains the second leading cause of cancer-related deaths worldwide,^[@bibr1-0300060519899780]^ and one of the four most common cancers in China.^[@bibr2-0300060519899780]^ Surgical resection is the primary method of treatment for non-metastatic GC and is curative in many cases but for some patients recurrence and metastases may occur which can be fatal.^[@bibr3-0300060519899780]^ Therefore, it is important to identify biomarkers which can assist in the identification of patients who are at risk of relapse.^[@bibr3-0300060519899780]^

Currently, the screening methods commonly used for GC include gastroscopy, barium meal imaging and computed tomography (CT). However, these methods have limited sensitivity, are not prognostic, tend to be invasive and can cause severe discomfort for the patient. Identification of tumour markers is becoming increasingly popular in clinical oncology as a non-invasive method for cancer diagnosis and for monitoring response to treatment; their use is simple and easily accepted by patients.^[@bibr4-0300060519899780]^

Alpha-fetoprotein (AFP) is a glycoprotein synthesized by the foetal yolk sac and liver during pregnancy,^[@bibr5-0300060519899780]^ and is a common marker of tumours of the digestive system. ^[@bibr6-0300060519899780]^ The diagnostic and prognostic value of AFP for hepatocellular carcinoma and yolk sac tumours has been determined, but serum levels may also be elevated in other cancers including primary GC.^[@bibr6-0300060519899780],[@bibr7-0300060519899780]^ Indeed, high AFP levels in GC accompanied by liver metastases were first reported in 1970.^[@bibr8-0300060519899780]^ Over subsequent decades, several studies have emphasised that patients with AFP-producing GC were at increased risks of lympho-vascular invasion and liver metastases, as well as a poor prognosis and aggressive cancer.^[@bibr9-0300060519899780][@bibr10-0300060519899780]--[@bibr11-0300060519899780]^ However, differences among studies in methodology and sample size has meant that the exact association between serum AFP levels and GC remains controversial.^[@bibr12-0300060519899780]^Therefore, we decided to conduct a meta-analysis of relevant studies to evaluate the relationship between pre-treatment serum AFP levels and clinical outcome of patients with GC.

Methods {#sec2-0300060519899780}
=======

PubMed, EMBASE, Medline and Web of Science databases were systematically searched for studies published between January 01, 1998 and December 31, 2018 that investigated AFP levels in patients with gastric cancer. Key words/terms in both AND and OR combinations included: alpha fetoprotein; AFP; gastric cancer; gastric carcinoma; gastric tumour; gastric neoplasm; survival; prognosis; outcome. For a published report to be included in the meta-analysis, it had to fulfil the following criteria: (1) be a clinical study of patients with GC; (2) report serum AFP levels for overall survival (OS), disease-free survival (DFS) and prognostic indicators; (3) provide hazard ratios (HR) and 95% confidence interval (CI) values. Duplicate publications, reviews, editorials, abstracts, comments, case reports, meetings and animal studies were excluded.

Two reviewers independently selected the published papers and any discrepancy was resolved by consultation with a third reviewer. The following information was extracted from each article: name of the first author; publication year; country of origin; sample size; sample year; survival analysis method; patient information (i.e., region, age, sex, tumour stage, cut-off value for AFP levels, and treatment); prognostic outcomes. If results from both univariate and multivariate analyses were provided, only multivariate analysis data were extracted. An email was also sent to authors requesting any missing relevant data. The quality of each of the studies was assessed according to the Newcastle--Ottawa Scale,^[@bibr13-0300060519899780]^ where a score of ≥6 was defined as a high-quality study.

The study was approved by the Ethics Committee of the Third Affiliated Hospital of Soochow University and because this was a meta-analysis of previously published articles, ethical approval was not required.

Statistical analyses {#sec3-0300060519899780}
--------------------

All statistical analyses were conducted using the soft-ware package Stata version12 (StataCorp, College Station, Texas). Cochran\'s Q test and Higgins\' I^2^ statistical test were used to assess the statistical heterogeneity of the pooled results. If I^2^ statistic ≥50% and *P* \< 0.05, a random effects model (DerSimonian--Laird method) was applied. If no heterogeneity was observed, a fixed effect model (Mantel--Haenszel method) was used. To assess possible sources of heterogeneity, subgroup analyses were performed based on country, sample size, tumour stage, treatment and cut-off values. A sensitivity analysis was applied to assess the robustness of the results. Begg's funnel plot and Egger\'s linear regression test were used to assess potential publication bias.

Results {#sec4-0300060519899780}
=======

The literature search identified 340 articles from which 13 articles ultimately met the eligibility criteria ([Figure 1](#fig1-0300060519899780){ref-type="fig"}).^[@bibr12-0300060519899780],[@bibr14-0300060519899780][@bibr15-0300060519899780][@bibr16-0300060519899780][@bibr17-0300060519899780][@bibr18-0300060519899780][@bibr19-0300060519899780][@bibr20-0300060519899780][@bibr21-0300060519899780][@bibr22-0300060519899780][@bibr23-0300060519899780][@bibr24-0300060519899780]--[@bibr25-0300060519899780]^ All 13 studies scored ≥6 (i.e., high-quality study) on the Newcastle--Ottawa Scale.^[@bibr13-0300060519899780]^ The main features of the 13 studies are summarized in [Table 1](#table1-0300060519899780){ref-type="table"}. Eight studies were performed in China, two in Turkey, two in Japan and one in South Korea. Apart from the Korean study, all were in English. Twelve articles contained data on OS and three had data on DFS. Treatments included surgery, chemotherapy and mixed therapy. All studies used multivariate analysis to determine the HRs.

![Flow diagram of included and excluded studies.](10.1177_0300060519899780-fig1){#fig1-0300060519899780}

###### 

Characteristics of the 13 studies included in the meta-analysis of the relationship between pre-treatment serum AFP levels and outcome in patients with gastric cancer.

![](10.1177_0300060519899780-table1)

  First author (year)                                   Country, Region     N      Age (y)               Men/women   Study period   Stage    Serum AFP cut-off value ng/ml   Treatment      Outcome   Follow-up duration (months)
  ----------------------------------------------------- ------------------- ------ --------------------- ----------- -------------- -------- ------------------------------- -------------- --------- -----------------------------
  Bozkaya et al. (2017)^[@bibr14-0300060519899780]^     Turkey, West Asia   362    median 58             267/95      2009--2015     I--III   9                               Mixed          OS/DFS    48
  Chen et al. (2015)^[@bibr12-0300060519899780]^        China, East Asia    1286   942/344(≤65/\>65y)    982/304     2004--2008     I--III   20                              Surgery        OS/DFS    60
  Chun and Kwon (2011)^[@bibr15-0300060519899780]^      China, East Asia    694    median 59             477/217     2001--2008     I--III   7                               Surgery        OS        38
  Dang et al. (2016)^[@bibr16-0300060519899780]^        China, East Asia    400    208/192(≥60/\<60y)    295/105     2010--2013     I--IV    20                              Mixed          OS        40
  Kochi et al. (2004)^[@bibr17-0300060519899780]^       Japan, East Asia    57     median 62             47/10       1989--2002     IV       20                              Chemotherapy   OS        NR
  Lew et al. (2013)^[@bibr18-0300060519899780]^         Korea, East Asia    771    mean 62               532/239     2005--2013     I--IV    10                              Mixed          OS        60
  Lin et al. (2014)^[@bibr19-0300060519899780]^         China, East Asia    1294   mean 66               1027/267    1988--2011     I--IV    20                              Surgery        OS        43
  Liu et al. (2016)^[@bibr20-0300060519899780]^         China, East Asia    1294   median 58             1010/284    2008--2014     I--III   8.1                             Surgery        OS        91
  Tachibana et al. (1998)^[@bibr21-0300060519899780]^   Japan, East Asia    196    108/88 (≤69/≥70y)     136/60      1986--1996     I--IV    NR                              Surgery        OS        120
  Ucar et al. (2008)^[@bibr22-0300060519899780]^        Turkey, West Asia   95     mean 58               63/32       2001--2005     I--IV    10                              Mixed          DFS       18
  Wang et al. (2015)^[@bibr23-0300060519899780]^        China, East Asia    634    287/347 (≥60/\<60y)   449/185     2009--2012     I--IV    7                               Surgery        OS        NR
  Wang et al. (2018)^[@bibr24-0300060519899780]^        China, East Asia    105    median 59             82/23       2006--2016     I--IV    500                             Chemotherapy   OS        60
  Xu et al. (2018)^[@bibr25-0300060519899780]^          China, East Asia    1911   815/1096(≥65/\<65y)   1549/362    2008--2014     I--III   8.1                             Mixed          OS        91

Abbreviations: AFP, alpha-fetoprotein; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; NR, not reported.

Twelve 12 studies involving 9004 patients assessed the association between pre-treatment serum AFP levels and OS. Pooled analysis showed that high serum AFP levels were associated with poor OS, compared with low pre-treatment serum AFP levels (HR = 1.90, 95% CI = 1.45, 2.49, *P* \< 0.001). However, heterogeneity between the studies was statistically significant (I^2^ = 73.30%, *P* \< 0.001) ([Figure 2](#fig2-0300060519899780){ref-type="fig"}).

![Forest plots of studies evaluating the association between pre-treatment serum AFP levels and gastric cancer. The squares and horizontal lines correspond to the study specific hazard ratios (HR) and 95% confidence intervals (CIs), respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary HR and 95% CI.](10.1177_0300060519899780-fig2){#fig2-0300060519899780}

Three studies involving 1743 patients assessed DFS. The combined results showed that high serum AFP levels were associated with poor DFS (HR = 2.08, 95% CI = 1.66--2.60, *P* \< 0.001) and heterogeneity between the studies was minimal ([Figure 2](#fig2-0300060519899780){ref-type="fig"}).

A series of subgroup analyses was performed based on country, sample size, tumour stage, treatment and cut-off values and assessed possible sources of heterogeneity ([Table 2](#table2-0300060519899780){ref-type="table"}). Results showed that studies of OS rates using 'non-China' countries (n = 4), sample size  \< 500 (n = 5), mixed treatment (n = 4), or AFP cut-off value ≥20 ng/ml (n = 5), all had low heterogeneity. All the other sub-groups had significant heterogeneity ([Table 2](#table2-0300060519899780){ref-type="table"}).

###### 

Summary of the subgroup analysis.

![](10.1177_0300060519899780-table2)

  Subgroup                  Outcome   No. studies   Number of patients   HR (95% CI)         Statistical significance   Model    Heterogeneity   
  ------------------------- --------- ------------- -------------------- ------------------- -------------------------- -------- --------------- --------------
  All variables             OS        12            9004                 1.90 (1.45, 2.49)   *P* \< 0.001               random   73.3%           *P* \< 0.001
                            DFS       3             1743                 2.08 (1.66, 2.60)   *P* \< 0.001               fixed    21.8%           ns
  Country                                                                                                                                        
   China                    OS        8             7618                 2.07 (1.49, 2.86)   *P* \< 0.001               random   80.3%           *P* \< 0.001
                            DFS       1             1286                 2.17 (1.70, 2.78)                                                       
   Other countries          OS        4             1386                 1.57 (1.10, 2.26)   *P* = 0.014                fixed    25.9%           ns
                            DFS       2             457                  1.65 (0.94, 2.89)   ns                         fixed    43.7%           ns
  Sample size                                                                                                                                    
   \>500                    OS        7             7884                 2.10 (1.50, 2.93)   *P* \< 0.001               random   83.0%           *P* \< 0.001
                            DFS       1             1286                 2.17 (1.70, 2.78)                                                       
    \< 500                  OS        5             1120                 1.53 (1.05, 2.24)   *P* = 0.027                fixed    3.7%            ns
                            DFS       2             457                  1.65 (0.94, 2.89)   ns                         fixed    43.7%           ns
  Stage                                                                                                                                          
   I--III                   OS        5             5547                 1.77 (1.28, 2.44)   0.001                      random   69.5%           *P = *0.011
                            DFS       2             1648                 2.17 (1.72, 2.74)   *P* \< 0.001               fixed    0               ns
   I--IV                    OS        7             3457                 1.94 (1.21, 3.10)   *P* = 0.006                random   76.7%           *P* \< 0.001
                            DFS       1             95                   1.00 (0.30, 1.90)                                                       
  Treatment                                                                                                                                      
   Surgery                  OS        6             5398                 2.12 (1.38, 3.24)   *P* = 0.001                random   83.8%           *P* \< 0.001
                            DFS       1             1286                 2.17 (1.70, 2.78)                                                       
   Mixed treatments         OS        4             3444                 1.45 (1.16, 1.83)   *P* = 0.001                fixed    0               ns
                            DFS       2             457                  1.65 (0.94, 2.89)   ns                         fixed    43.7%           ns
  Serum AFP cut-off value                                                                                                                        
   ≥20 ng/ml                OS        5             3142                 2.11 (1.77, 2.52)   *P* \< 0.001               fixed    0               ns
                            DFS       1             1286                 2.17 (1.70, 2.78)                                                       
    \< 20 ng/ml             OS        6             5666                 2.03 (1.26, 3.25)   *P* = 0.003                random   84.5%           *P* \< 0.001
                            DFS       2             457                  1.65 (0.94, 2.89)   ns                         fixed    43.7%           ns

Abbreviations: OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; ns, not statistically significant.

Sensitivity analysis of the OS rates was performed to examine the effects of each individual study on the combined HR. The results of this analysis showed that the omission of each study did not significantly alter the overall results indicating that our analysis result was robust ([Figure 3](#fig3-0300060519899780){ref-type="fig"}). In addition, the results from Begg's funnel plot and Egger's test indicated that there was no significant publication bias in this meta-analysis ([Figure 4](#fig4-0300060519899780){ref-type="fig"}).

![Sensitivity analysis of the relationship between pre-treatment serum AFP levels and overall survival (OS) rates to confirm the robustness of the results by removing one study at a time.](10.1177_0300060519899780-fig3){#fig3-0300060519899780}

![Funnel plot for evaluating potential publication bias.](10.1177_0300060519899780-fig4){#fig4-0300060519899780}

Discussion {#sec5-0300060519899780}
==========

This meta-analysis included data from 13 studies involving 9099 patients with GC. With regard to the quality of the evidence, the risk of bias was minimal as indicated by Begg's funnel plot and Egger\'s test. In addition, a sensitivity analysis showed that omission of each study did not significantly alter the overall results indicating that the analysis was robust. Pooled analysis of the 12 studies that assessed OS showed a significant correlation between elevated pre-treatment serum AFP levels and poor prognosis in patients with GC. However, there was substantial heterogeneity among the studies. Nevertheless, a subgroup analysis found that studies using 'non-China' countries, sample size  \< 500, mixed treatment or AFP cut-off values ≥20 ng/ml had low, heterogeneity (i.e., I^2^ \< 50%).

In spite of many treatment options for GC, the 5-year survival rate is low and poor prognosis is mainly due to local recurrence, lymphatic invasion and distant metastasis.^[@bibr26-0300060519899780]^ Therefore, it is important to identify new reliable biomarkers to improve early detection of the cancer and assess its prognosis. In clinical practice, AFP is considered to be a useful tumour marker for hepatocellular carcinoma and yolk sac tumors,^[@bibr6-0300060519899780],[@bibr27-0300060519899780]^ and some studies have shown that serum AFP levels are also elevated in a variety of extrahepatic tumours, including those of the stomach, lung, pancreas, colon, bladder and ovary.^[@bibr6-0300060519899780]^ Of these cancers, GC is the most common type that is accompanied by high serum AFP levels.^[@bibr6-0300060519899780]^Although AFP is a useful biomarker for predicting survival and detecting and/or monitoring hepatocellular carcinoma, its correlation with GC remains to be clarified.^[@bibr12-0300060519899780]^

Since both the stomach and liver were derived from the original foregut of the embryo, it has been suggested that GCs may produce large amounts of AFP in the same manner as liver cancer when there is an abnormality during differentiation. ^[@bibr28-0300060519899780]^Indeed, the concept of a hepatoid adenocarcinoma of the stomach has been proposed for primary GC that is characterized by hepatoid differentiation and production of large amounts of AFP. ^[@bibr28-0300060519899780]^ However, other authors have suggested that AFP-producing GCs are not always derived from hepatocyte differentiation and AFP in primary GC may be a gastrointestinal-specific foetal protein.^[@bibr29-0300060519899780]^ Another study proposed that AFP has immunosuppressive functions and inhibits the production of cytokines, interferons, and tumour necrosis factor by natural killer cells and macrophages. ^[@bibr30-0300060519899780]^ The authors suggested that in the presence of AFP, cancer cells grow rapidly and can cause distant metastases following blood vessel invasion.^[@bibr30-0300060519899780]^ In addition, it has been reported that the prognosis for AFP-producing GC is worse than that for AFP-negative GC, because the former is characterized by aggressive biological behaviour and high potential for liver metastasis. ^[@bibr6-0300060519899780],[@bibr15-0300060519899780]^ Corroborating this observation, other authors have found that high levels of serum AFP were associated with shorter survival times and that patients with high serum AFP had high frequencies of liver and lymph node metastasis with poor prognosis.^[@bibr19-0300060519899780]^ Accordingly, the treatment of these patients may require multimodal therapy (i.e., chemotherapy, radiotherapy, biotherapy).^[@bibr12-0300060519899780],[@bibr15-0300060519899780]^

The study had some limitations. For example, there were only 13 studies and eight were performed in China which may have introduced some bias. In addition, the numbers of studies in the sub-group analyses were low which may have influenced heterogeneity. Furthermore, the serum AFP cut-off values differed among studies which may also have led to imbalance. Therefore, future research is required to clarify accurately the association between pre-treatment serum AFP levels and the prognosis of patients with GC. We will continue to search for high quality articles and update our meta-analysis accordingly.

The results of this meta-analysis suggest that pre-treatment serum AFP levels are an independent prognostic factor for assessing the outcome of patients with GC. High levels of pre-treatment serum AFP were associated with a poor prognosis. Therefore, patients with high serum AFP levels should be closely monitored and have frequent follow-up visits using tests such as computed tomography (CT), magnetic resonance imaging, positron emission tomography/CT as deemed necessary.
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